细菌在肿瘤治疗中应用的研究进展
Advances in the Application of Bacteria in Tumor Therapy
DOI: 10.12677/hjbm.2024.142024, PDF,   
作者: 张 媛*, 陈 欢#:中国药科大学生命科学与技术学院,江苏 南京
关键词: 细菌肿瘤治疗合成生物学免疫治疗工程化细菌Bacteria Tumor Therapy Synthetic Biology Immunotherapy Engineered Bacteria
摘要: 近年来,肿瘤治疗的手段不断取得新的突破,在传统的手术、化疗、放疗对肿瘤治疗存在各自局限的现状下,突破性地开发出肿瘤免疫疗法,虽然其在血液瘤、多发性骨髓瘤等治疗中取得了成功,但是对实体性肿瘤的治疗仍达不到理想效果,因此亟待新的肿瘤治疗手段的开发。细菌肿瘤疗法早有先例,但是因为其应用的安全性考量以及不能清楚阐明治疗的具体机制而未受到重视,随着生物技术的蓬勃发展,改造细菌能使其满足治疗使用的要求,越来越多关于细菌在肿瘤治疗中的应用报道。本篇综述总结了细菌在肿瘤治疗中的优势、几种常用的细菌以及细菌在肿瘤治疗中的策略,以期为开发新的肿瘤治疗手段提供理论依据和新思路。
Abstract: In recent years, new breakthroughs have been made in the means of tumor treatment. Under the current situation that traditional surgery, chemotherapy and radiotherapy have their own limitations in the treatment of tumor, tumor immunotherapy has been breakthrough developed. Although it has achieved success in the treatment of hematoma and multiple myeloma, the treatment of solid tumor still fails to achieve the ideal effect. Therefore, it is urgent to develop new tumor treatment methods. Bacterial tumor therapy has a precedent for a long time, but it has not been paid attention to because of the safety considerations of its application and the failure to clearly clarify the specific mechanism of treatment. With the vigorous development of biotechnology, bacteria can be modified to meet the requirements of therapeutic use, and more and more reports on the application of bacteria in tumor therapy are reported. The article summarizes the advantages of bacteria in tumor therapy, several commonly used bacteria and the strategies of bacteria in tumor therapy, in order to provide theoretical basis and new ideas for the development of new tumor therapy.
文章引用:张媛, 陈欢. 细菌在肿瘤治疗中应用的研究进展[J]. 生物医学, 2024, 14(2): 221-228. https://doi.org/10.12677/hjbm.2024.142024

参考文献

[1] Kocijancic, D., Felgner, S., Frahm, M., et al. (2016) Therapy of Solid Tumors Using Probiotic Symbioflor-2—Restraints and Potential. Oncotarget, 7, 22605-22622. [Google Scholar] [CrossRef] [PubMed]
[2] HoptionCann, S.A., Van Netten, J.P. and Van Netten, C. (2003) Dr William Coley and Tumour Regression: A Place in History or in the Future. Postgraduate Medical Journal, 79, 672-680. [Google Scholar] [CrossRef
[3] Choi, Y., Lichterman, J.N., Coughlin, L.A., et al. (2023) Immune Checkpoint Blockade Induces Gut Microbiota Translocation That Augments Extraintestinal Antitumor Immunity. Science Immunology, 8, Eabo2003. [Google Scholar] [CrossRef] [PubMed]
[4] Bender, M.J., McPherson, A.C., Phelps, C.M., et al. (2023) Dietary Tryptophan Metabolite Released by Intratumoral Lactobacillus reuteri Facilitates Immune Checkpoint Inhibitor Treatment. Cell, 186, 1846-1862.E26. [Google Scholar] [CrossRef] [PubMed]
[5] Galeano Niño, J.L., Wu, H., LaCourse, K.D., et al. (2022) Effect of the Intratumoral Microbiota on Spatial and Cellular Heterogeneity in Cancer. Nature, 611, 810-817. [Google Scholar] [CrossRef] [PubMed]
[6] Fu, A., Yao, B., Dong, T., et al. (2022) Tumor-Resident Intracellular Microbiota Promotes Metastatic Colonization in Breast Cancer. Cell, 185, 1356-1372.E26. [Google Scholar] [CrossRef] [PubMed]
[7] Nolan, E., Bridgeman, V.L., Ombrato, L., et al. (2022) Radiation Exposure Elicits a Neutrophil-Driven Response in Healthy Lung Tissue That Enhances Metastatic Colonization. Nature Cancer, 3, 173-187. [Google Scholar] [CrossRef] [PubMed]
[8] Zheng, J.H., Nguyen, V.H., Jiang, S.-N., et al. (2017) Two-Step Enhanced Cancer Immunotherapy with Engineered Salmonella typhimurium Secreting Heterologous Flagellin. Science Translational Medicine, 9, Eaak9537. [Google Scholar] [CrossRef] [PubMed]
[9] Forbes, N.S., Munn, L.L., Fukumura, D., et al. (2003) Sparse Initial Entrapment of Systemically Injected Salmonella typhimurium Leads to Heterogeneous Accumulation within Tumors. Cancer Research, 63, 5188-5193.
[10] Tang, Q., Peng, X., Xu, B., et al. (2022) Current Status and Future Directions of Bacteria-Based Immunotherapy. Frontiers in Immunology, 13, Article ID: 911783. [Google Scholar] [CrossRef] [PubMed]
[11] Leventhal, D.S., Sokolovska, A., Li, N., et al. (2020) Immunotherapy with Engineered Bacteria by Targeting the STING Pathway for Anti-Tumor Immunity. Nature Communications, 11, Article No. 2739. [Google Scholar] [CrossRef] [PubMed]
[12] Fang, R., Jiang, Q., Jia, X., et al. (2023) ARMH3-Mediated Recruitment of PI4KB Directs Golgi-to-Endosome Trafficking and Activation of the Antiviral Effector STING. Immunity, 56, 500-515.E6. [Google Scholar] [CrossRef] [PubMed]
[13] Zhang, X., Bai, X.-C. and Chen, Z.J. (2020) Structures and Mechanisms in the CGAS-STING Innate Immunity Pathway. Immunity, 53, 43-53. [Google Scholar] [CrossRef] [PubMed]
[14] Yu, X., Lin, C., Yu, J., et al. (2019) Bioengineered Escherichia coli Nissle 1917 for Tumour-Targeting Therapy. Microbial Biotechnology, 13, 629-636. [Google Scholar] [CrossRef] [PubMed]
[15] Behnsen, J., Deriu, E., Sassone-Corsi, M., et al. (2013) Probiotics: Properties, Examples, and Specific Applications. Cold Spring Harbor Perspectives in Medicine, 3, A010074. [Google Scholar] [CrossRef] [PubMed]
[16] Reister, M., Hoffmeier, K., Krezdorn, N., et al. (2014) Complete Genome Sequence of the Gram-Negative Probiotic Escherichia coli Strain Nissle 1917. Journal of Biotechnology, 187, 106-107. [Google Scholar] [CrossRef] [PubMed]
[17] Clairmont, C., Lee, K.C., Pike, J., et al. (2000) Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain of Salmonella typhimurium. The Journal of Infectious Diseases, 181, 1996-2002. [Google Scholar] [CrossRef] [PubMed]
[18] Toso, J.F., Gill, V.J., Hwu, P., et al. (2002) Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients with Metastatic Melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 20, 142-152. [Google Scholar] [CrossRef
[19] Zhou, D.-X., Wang, X.-H., Xu, X., et al. (2022) Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-MPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy. Pharmaceutics, 14, Article No. 2789. [Google Scholar] [CrossRef] [PubMed]
[20] Pawelek, J.M., Low, K.B. and Bermudes, D. (1997) Tumor-Targeted Salmonella as a Novel Anticancer Vector. Cancer Research, 57, 4537-4544.
[21] Garza-Morales, R., Rendon, B.E., Malik, M.T., et al. (2020) Targeting Melanoma Hypoxia with the Food-Grade Lactic Acid Bacterium Lactococcus lactis. Cancers, 12, Article No. 438. [Google Scholar] [CrossRef] [PubMed]
[22] Feizollahzadeh, S., Khanahmad, H., Rahimmanesh, I., et al. (2016) Expression of Biologically Active Murine Interleukin-18 in Lactococcus lactis. FEMS Microbiology Letters, 363, Fnw234. [Google Scholar] [CrossRef] [PubMed]
[23] Zhu, J., Ke, Y., Liu, Q., et al. (2022) Engineered Lactococcus lactis Secreting Flt3L and OX40 Ligand for in Situ Vaccination-Based Cancer Immunotherapy. Nature Communications, 13, Article No. 7466. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, H.-Y., Man, J.-H., Liang, B., et al. (2010) Tumor-Targeted Delivery of Biologically Active TRAIL Protein. Cancer Gene Therapy, 17, 334-343. [Google Scholar] [CrossRef] [PubMed]
[25] Malla, W.A., Arora, R., Khan, R.I.N., et al. (2020) Apoptin as a Tumor-Specific Therapeutic Agent: Current Perspective on Mechanism of Action and Delivery Systems. Frontiers in Cell and Developmental Biology, 8, Article No. 524. [Google Scholar] [CrossRef] [PubMed]
[26] Guan, G., Zhao, M., Liu, L., et al. (2013) Salmonella typhimurium Mediated Delivery of Apoptin in Human Laryngeal Cancer. International Journal of Medical Sciences, 10, 1639-1648. [Google Scholar] [CrossRef] [PubMed]
[27] Zhang, Y.-L., Lü, R., Chang, Z.-S., et al. (2014) Clostridium Sporogenes Delivers Interleukin-12 to Hypoxic Tumours, Producing Antitumour Activity without Significant Toxicity. Letters in Applied Microbiology, 59, 580-586. [Google Scholar] [CrossRef] [PubMed]
[28] Loeffler, M., Le’Negrate, G., Krajewska, M., et al. (2007) Attenuated Salmonella Engineered to Produce Human Cytokine LIGHT Inhibit Tumor Growth. Proceedings of the National Academy of Sciences of the United States of America, 104, 12879-12883. [Google Scholar] [CrossRef] [PubMed]
[29] Savage, T.M., Vincent, R.L., Rae, S.S., et al. (2023) Chemokines Expressed by Engineered Bacteria Recruit and Orchestrate Antitumor Immunity. Science Advances, 9, Eadc9436. [Google Scholar] [CrossRef] [PubMed]
[30] Namai, F., Murakami, A., Ueda, A., et al. (2020) Construction of Genetically Modified Lactococcus lactis Producing Anti-Human-CTLA-4 Single-Chain Fragment Variable. Molecular Biotechnology, 62, 572-579. [Google Scholar] [CrossRef] [PubMed]
[31] Gurbatri, C.R., Lia, I., Vincent, R., et al. (2020) Engineered Probiotics for Local Tumor Delivery of Checkpoint Blockade Nanobodies. Science Translational Medicine, 12, Eaax0876. [Google Scholar] [CrossRef] [PubMed]
[32] Vincent, R.L., Gurbatri, C.R., Li, F., et al. (2023) Probiotic-Guided CAR-T Cells for Solid Tumor Targeting. Science, 382, 211-218. [Google Scholar] [CrossRef] [PubMed]
[33] Song, P., Han, X., Li, X., et al. (2023) Bacteria Engineered with Intracellular and Extracellular Nanomaterials for Hierarchical Modulation of Antitumor Immune Responses. Materials Horizons, 10, 2927-2935. [Google Scholar] [CrossRef
[34] Wu, W., Pu, Y., Gao, S., et al. (2022) Bacterial Metabolism-Initiated Nanocatalytic Tumor Immunotherapy. Nano-Micro Letters, 14, Article No. 220. [Google Scholar] [CrossRef] [PubMed]
[35] Ma, X., Liang, X., Li, Y., et al. (2023) Modular-Designed Engineered Bacteria for Precision Tumor Immunotherapy via Spatiotemporal Manipulation by Magnetic Field. Nature Communications, 14, Article No. 1606. [Google Scholar] [CrossRef] [PubMed]